期刊论文

Influence of compound liver prescription on intestinal microbiota in mice with primary hepatic carcinoma

中文

湖南中医杂志

1003-7705

2017

33

7

167-169

10.16808/j.cnki.issn1003-7705.2017.07.076

湖南省中医药管理局科研计划项目（编号:201654）；

本校为第一机构

目的：探讨肝复方对原发性肝癌（PHC）模型小鼠肠道菌群的影响,为肝复方治疗PHC的作用机制提供实验依据。方法：于92只ICR小鼠中取32只,随机分为正常1组与模型1组,每组16只,观察PHC小鼠造模前后肠道菌群的变化。另60只随机分为正常2组、模型2组、益生菌组、肝复方组,每组15只。肝复方组给予肝复方灌胃,剂量为15.6mg/（kg·d）,模型2组、正常2组分别给予等量无菌水灌胃,益生菌组给予益生菌VSL#3灌胃,剂量为6mg/（kg·d）。每天灌胃1次,灌胃剂量均为临床等效剂量,连续用药14d。观察肝复方对PHC小鼠肠道菌群的影响。结果：PHC小鼠造模后双歧杆菌、乳酸杆菌、大肠埃希菌、肠球菌数量均多于造模前,差...

Objective： To investigate the influence of compound liver prescription on intestinal microbiota in mice with primary hepatic carcinoma（ PHC）,and to provide an experimental basis for the mechanism of action of compound liver prescription in the treatment of PHC. Methods： A total of 92 ICR mice were selected; 32 of them were randomly divided into normal group 1 and model group 1,with 16 mice in each group,and the change in intestinal microbiota after modeling was observed. The other 60 mice were randomly divided into normal group 2,model grou...